VIEKIRA PAK (ritonavir-boosted paritaprevir/ombitasvir and dasabuvir) is an approved treatment for compensated patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This oral regimen has minimal adverse effects and is well tolerated. Cure rates are 97% in patients infected with HCV GT 1a and 99% in those with HCV GT 1b. We report the first case of life-threatening allergic pneumonitis associated with VIEKIRA PAK. This unexpected serious adverse event occurred in a 68-year-old Chinese female with genotype 1b chronic hepatitis C and Child-Pugh A cirrhosis. One week into treatment with VIEKIRA PAK without ribavirin, she was admitted to hospital with respiratory distress and acute kidney injury requiring intensive care input. She was initially diagnosed with community acquired pneumonia and improved promptly with intravenous antibiotics and supported care. No bacterial or viral pathogens were cultured. Following complete recovery, she recommenced VIEKIRA PAK but represented 5 days later with more rapidly progressive respiratory failure, requiring intubation and ventilation, inotropic support, and haemodialysis. The final diagnosis was drug induced pneumonitis.
Introduction: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Recent findings have demonstrated a mechanistic link between inflammatory and the development of AF. Macrophage migration inhibitory factor (MIF), a pleiotropic cytokine, controls the inflammatory ‘set point’ by regulating the release of other pro-inflammatory cytokines. Recent studies have revealed that Connexin 43 (Cx 43) not only is involved in the electrical conductivity between the cells, but also forms a complex with PKP2 and Na+ channel to affect the sodium current. The purpose of this study is to observe the role of MIF in the expression of Cx43, and the role of Cx43 in the regulation of calcium channel current in atrial myocytes.